These models were treated with FAK inhibitor IN10018 as monotherapy or in combination with anti-PD-1 immunotherapy.<h4>Results</h4>FAK was highly expressed and frequently amplified in HCC tumors, which predicted worse pathological features of patients. Here, PTK2 is linked to hepatocellular carcinoma.